Factors Associated With Early Termination of CHOP Therapy and the Impact on Survival among Patients with Chemosensitive Intermediate-Grade Non-Hodgkin's Lymphoma

Cancer Control

Volumn 10, Issue 5, 2003, Pages 396-403

  Chrischilles, Elizabeth A ^a   Link, Brian K ^a   Scott, Shane D ^a   Delgado, David J ^b   Fridman, Moshe ^c  

^a UNIVERSITY OF IOWA   (United States)

^b AMGEN INC   (United States)

^c AMF Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHEMOSENSITIVITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; UNITED STATES;

EID: 0142085807     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000507     Document Type: Article

References (18)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
3. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484-1493.
4. Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1988;24:533-538.
5. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.
6. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
7. Lyman G, Dale D, Crawfold J, et al. Risk of febrile neutropenia among patients receiving CHOP chemotherapy. Blood. 2001;98:4642. Abstract.
8. Weiner N, Fridman M, Steinberg D, et al. A model to predict chemotherapy related neutropenic events in intermediate and high grade lymphoma (IHL) patients. Blood. 1998;92:2564. Abstract.
9. Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065-2069.
10. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial chop chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47-56.
11. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
13. Romano PS, Roos LL, JoUis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079.
14. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
15. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Kouroukis CT, Browman GP, Esmail R, et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin's lymphoma: a systematic review. Ann Intern Med. 2002;136:136-143.
18. Peters FP, Fickers MM, Erdkamp FL, et al. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol. 2001;80:406-410.